152 results on '"Patil, V M"'
Search Results
2. Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial
- Author
-
Noronha, V., Patil, V. M., Menon, N. S., Joshi, A., Goud, S., More, S., Kannan, S., Pawar, A., Nakti, D., Yadav, A., Shah, S., Mahajan, A., Janu, A., Kumar, R., Tibdewal, A., Mummudi, N., Agarwal, J. P., Banavali, S. D., and Prabhash, K.
- Published
- 2022
- Full Text
- View/download PDF
3. Constraints perceived by the livestock farmers in management of Khillar cattle of Karnataka
- Author
-
Rajashekhar, K., primary, Jagadeeswary, V., additional, Satyanarayan, K., additional, Kumar, S. Naveen, additional, Patil, V. M., additional, and Shree, J. Shilpa, additional
- Published
- 2023
- Full Text
- View/download PDF
4. To Study the Effectiveness of the Organic Ectoparasiticide "GochidGo" against Cattle Tick Infection in Maharashtra, India
- Author
-
Patil, V. M., primary and Patil, S. B., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Biological control of date palm red mite Raoiella indica using organic miticide.
- Author
-
Patil, V. M. and Patil, S. B.
- Subjects
- *
DATE palm , *ACARICIDES , *MITES , *NON-target organisms , *ABAMECTIN , *BANANAS - Abstract
The red palm mite Raoiella indica Hirst is spread throughout the Caribbean islands, Florida, northern South America, and Mexico, and it negatively impacts palm and banana species. Different acaricides were used to control R. indica infestations of date palms in the UAE, but the majority of these acaricides are strong chemicals with high toxicity to nontarget pests. The present study was conducted in the UAE on the red palm mite R. indica on infected date palms. One of the commercial botanical acaricides, namely M Impact, was tested for the control of R. indica in comparison with a market product containing abamectin. Raoiella indica mortality was 79.40% after the first spray and 70.23% after the second spray in the treatment of M Impact, with a 58.4% reduction in eggs. In the market product containing 3.5% w/v abamectin, mortality was 46.53% after the first spray and 41.22% after the second spray, with a 34.2% reduction in egg mortality. In this study, it was demonstrated that the organic miticide M Impact outperformed its chemical counterpart, abamectin. Organic miticides have provided significant and long-term control of the date palm red mite, R. indica. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Socio-economic profile of Kalyana Gidda cattle rearing farmers of Northern Karnataka.
- Author
-
Mundinamani, V. I., Gouri, M. D., Patil, V. M., R., Guruprasad, H. M., Yathish, T. M., Prabhu, and C., Kotresh Prasad
- Subjects
ANIMAL culture ,CATTLE ,INCOME ,AGRICULTURE ,MILK yield ,DAIRY cattle ,LACTATION in cattle - Abstract
The study was conducted among 60 farmers to know the socio economic status of the farmers owning Kalyana Gidda cattle in Raichur and Yadgir districts of Northern Karnataka and they were exposed to a structured interview schedule. The study found that the family type of the respondents was majorly joint type and most of the respondents were in middle age category, followed by old age and young age category. It was found that majority of the farmers had no education followed by primary education and large majority of the respondents had agriculture as their primary occupation followed by agricultural labour, business and animal husbandry. It was evident from the results that the majority of the farmers had animal husbandry (66.66 %) as secondary occupation. A considerable size (35 %) of the respondents belonged to small farmers category, followed by 33.33, 18.33, 8.33, and 5 % of respondents belonged to medium, marginal, large and landless category, respectively. The family income of most of the farmers (70 %) was below Rs. 40,000 followed by Rs. 40,000 to Rs. 80,000 (23.33 %) and only 6.67 % of them had higher income (>Rs. 80,000). It was observed that the average breeding bull holding by the farmers in the study area was higher in Yadgir block followed by Devadurga, Lingasugur and Surapur. Similar trend was observed for male and female calves holding. The average milking female holding was highest in Devadurga block followed by Yadgir, the female holding of Surpur and Lingasurgur was lesser. Similar trend was observed for bullock holding. The average milk yield recorded among all blocks was 2.27 L/day/cow in Kalyana Gidda cows. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Impact of social housing and social separation on haematological and physiological parameters in Syrian male hamsters
- Author
-
Kumar, A., primary, Rajeshwari, Y. B., primary, Patil, V. M., primary, Yadav, R. R., primary, Ali, S. M., primary, Shaswath, G. S., primary, Bhandekar, S. K., primary, Katiyar, A., primary, Durrani, M. K., primary, and Karan, P., primary
- Published
- 2021
- Full Text
- View/download PDF
8. ALK positive lung cancer: Clinical profile and outcomes in a developing country: 175P
- Author
-
Ramaswamy, A., Patil, V. M., Noronha, V., Joshi, A., Chougule, A., Kaushal, R., Nayak, L., Doshi, V., Mahajan, A., and Prabhash, K.
- Published
- 2016
- Full Text
- View/download PDF
9. A Piece of Wooden Stick as a Crime Scene Evidence to Solve The Murder Mystery
- Author
-
Chaudhari, S.V. Patil, primary, Patil, V. M., additional, Rasherao, A. S., additional, More, P. V., additional, Gosavi, N.R., additional, Shinde, S. A., additional, and Kulkarni, K.V., additional
- Published
- 2018
- Full Text
- View/download PDF
10. Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study
- Author
-
Noronha, V, primary, Goswami, C, additional, Patil, S, additional, Joshi, A, additional, Patil, V M, additional, Murthy, V, additional, Arya, S, additional, Juvekar, S, additional, Goud, S, additional, and Prabhash, K, additional
- Published
- 2016
- Full Text
- View/download PDF
11. Locoregional recurrences after post-operative volumetric modulated arc radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting: experience and lessons learned
- Author
-
Chakraborty, S, primary, Patil, V M, additional, Babu, S, additional, Muttath, G, additional, and Thiagarajan, S K, additional
- Published
- 2015
- Full Text
- View/download PDF
12. Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy.
- Author
-
Noronha, V., Sharma, V., Joshi, A., Patil, V. M., Laskar, S. G., and Prabhash, K.
- Subjects
CANCER chemotherapy ,CISPLATIN ,CARBOPLATIN ,CANCER treatment ,CANCER patients ,ANTINEOPLASTIC agents ,HEAD tumors ,LONGITUDINAL method ,NECK tumors ,RETROSPECTIVE studies ,PHARMACODYNAMICS ,THERAPEUTICS - Abstract
Background: Cisplatin-based chemoradiation (CTRT) is the standard of care in locally advanced head and neck cancers. Limited treatment options are available in patients unfit for cisplatin.Aims: This audit was carried out to study the toxicities, tolerance, and outcomes of carboplatin-based CTRT in patients who are not eligible for cisplatin.Materials and Methods: A total of 63 locally advanced head and neck cancer patients treated between January 2011 and October 2015 were administered carboplatin-based CTRT. The dose of carboplatin was equivalent to area under the curve equivalent to 2 administered once a week for a maximum of 7 cycles. Toxicity was coded as per the CTCAE version 4.03. SPSS software version 16 was used for statistical analysis.Statistical Analysis: Descriptive statistics was performed. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier survival analysis. Cox proportional hazard model was used for identifying factors affecting PFS and OS.Results: The reasons for patients being unfit for cisplatin were low serum creatinine clearance in 41 (65.07%), sensorineural hearing loss in 18 (28.57%), uncontrolled medical comorbidities in 3 (4.76%), and old age in 1 patient (1.6%). 53 patients (84.1%) completed planned radiotherapy. The median number of chemotherapy cycles administered was 6. Grade 3-4 toxicities were seen in 32 patients (50.8%). The median OS and PFS were 28 months (95% confidence interval [CI]: 20.9-34.6 months) and 17 months (95% CI: 08.2-25.7 months), respectively. Age was the only factor significantly affecting OS and PFS.Conclusion: Carboplatin-based CTRT is well tolerated in patients unfit for cisplatin and seems to have superior outcomes than those reported in radical radiotherapy studies. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
13. Rechallenge temozolomide in glioma: A case series from India.
- Author
-
Patil, V. M., Tonse, R., Kothari, R., Chandrasekaran, A., Pande, N., Epari, S., Gupta, T., and Jalali, R.
- Subjects
- *
CANCER chemotherapy , *TEMOZOLOMIDE , *RADIOTHERAPY , *CANCER treatment , *ANTINEOPLASTIC agents , *GLIOMA treatment , *GLIOBLASTOMA multiforme , *ALKYLATING agents - Abstract
Introduction: Temozolomide (TMZ) is an integral part of upfront treatment of high-grade gliomas. It is administered postsurgery as concurrent therapy with radiation and subsequently as adjuvant chemotherapy for 6-12 cycles. It is unknown whether rechallenge of salvage TMZ in previously treated high-grade glioma has any efficacy.Material and Methods: Patients treated with salvage rechallenged TMZ between January 2015 and August 2016 were included for this retrospective analysis. SPSS version 20 was used for this analysis. Time to event analysis was performed using the Kaplan-Meier method. Progression-free survival (PFS) and overall survival (OS) were estimated. The maximum grade of toxicity was noted in accordance with CTCAE version 4.02.Results: A total of 23 patients were selected for analysis with the median age being 43 years (range: 26-69 years). The tumor histopathology at baseline was astrocytoma Grade 2 in 1 patient, oligodendroglioma Grade 2 in 3 patients, anaplastic astrocytoma in 7 patients, anaplastic oligodendroglioma in 2 patients, and glioblastoma in 10 patients. All of them had previously received TMZ. The median numbers of previous TMZ cycles received were 6 (4-18). The median time to failure postlast treatment was 24 months (5-72 months). The median number of cycles of rechallenged salvage TMZ administered was 6 cycles (range: 1-18). Grade 3-4 myelosuppression was seen in 3 patients (13.4%). The median PFS was 459 days (95% confidence interval: 212.1-705.9). The median OS was 25 months. Six-month OS and 1-year OS were 81.4% and 75.1%, respectively.Conclusion: Rechallenge with TMZ in recurrent glioma that had previously responded to TMZ is associated with improvement in PFS and OS and has a sufficiently long disease-free interval. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
14. Epidermal growth factor receptor positive lung cancer: The nontrial scenario.
- Author
-
Noronha, V., Patil, V. M., Joshi, A., Tandon, N., Sharma, V., Ramaswamy, A., More, S. B., Gaud, S., and Prabhash, K.
- Subjects
- *
EPIDERMAL growth factor receptors , *LUNG cancer , *NON-small-cell lung carcinoma , *MULTIVARIATE analysis , *ONCOLOGY , *CLINICAL trials , *EPIDERMAL growth factor , *LUNG tumors , *GENETIC mutation , *PROGNOSIS , *TUMOR classification , *PROTEIN kinase inhibitors , *KAPLAN-Meier estimator - Abstract
Purpose: The aim of this study was to report the median overall survival (OS) in epidermal growth factor receptor (EGFR) mutation-positive patients who were managed out of a clinical trial.Methods: Nonsmall cell lung cancer patients harboring activating EGFR mutations who were either ineligible or refused participation in a clinical trial were selected for this analysis. The reason for not participating in trial, staging, treatment, and outcome details were obtained from a prospective lung cancer database. The Kaplan-Meier method was used to estimate OS. Log-rank test and Cox proportion hazard model were used for univariate and multivariate analysis, respectively.Results: We included 225 patients in this analysis. The median age of the cohort was 56 years (range 29-85 years). A compromised Eastern Cooperative Oncology Group performance status (PS) of >2 was the major reason (83 patients, 36.9%) for ineligibility of patients in a clinical trial. The major reason provided by eligible patients for refusal to participate in a clinical trial was long distance of travel and inability to comply with the study-mandated follow-up visits (65 patients, 28.9%). The median OS in patients with PS 0-2 was 18.17 months (95% confidence interval [CI]: 15.6-20.8 months) and it was 12.1 months (95% CI: 9.0-15.2 months) in patients with PS 3-4 (hazard ratio - 0.579 [95% CI: 0.398-0.843] P = 0.004).Conclusion: EGFR positive patients who were ineligible for a clinical trial due to poor PS had lower survival; however, patients with good PS treated off-trial had similar OS to that reported in multiple clinical trials. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
15. Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer.
- Author
-
Patil, V. M., Noronha, V., Joshi, A., Nayak, L., Pande, N., Chandrashekharan, A., Dhumal, S., Bhattacharjee, A., Banavali, S., and Prabhash, K.
- Subjects
- *
CANCER chemotherapy , *HEAD & neck cancer treatment , *RANDOMIZED controlled trials , *DATA analysis , *ONCOLOGY , *ANTINEOPLASTIC agents , *HEAD tumors , *NECK tumors , *PALLIATIVE treatment , *RETROSPECTIVE studies - Abstract
Background: Metronomic chemotherapy has shown promising results in selected patients of head and neck cancer in a small randomized study. This retrospective analysis was done to see whether the efficacy of metronomic chemotherapy in an unselected cohort of head and neck cancer patients is similar to that reported in the randomized study and the influence of the site and subsite of head and neck cancer on survival.Materials and Methods: This was a retrospective analysis of head and neck cancer patients who received palliative metronomic chemotherapy between January 2013 and February 2015. The data of these patients were collected from our palliative chemotherapy database maintained in medical oncology outpatient department. The overall survival (OS) was calculated in days from the date of start of chemotherapy to the date of death. Patients who had not expired at last follow-up were censored during estimation of OS by Kaplan-Meier method. Factors affecting OS were identified by COX regression analysis.Results: Over the stipulated time period, 340 patients received palliative metronomic chemotherapy. The median age of these patients was 48 years (22-90 years). The sites of tumor origin were oral cavity in 281 patients (82.6%), oropharynx in 33 patients (9.7%), larynx in seven patients (2.1%), hypopharynx in 12 patients (3.5%), and maxilla in seven patients (2.1%). Previous treatment was received by 286 patients (84.1%). The median time to failure was 3.5 months (interquartile range 2.0-6.0 months). The overall median survival was 155 days (95% confidence interval 140.2-169.8 days). Failure within 6 months of previous treatment was the most important factor influencing OS. There was a trend toward lower OS in patients with oral cancers (139 days vs. 210 days). Among the various oral cancer subsites, oral tongue primary had a lower OS.Conclusion: Oral metronomic chemotherapy has promising results when used in a selected cohort of patients but has dismal results in patients who failed within 6 months of previous treatment. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
16. Comparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers.
- Author
-
Patil, V. M., Noronha, V., Joshi, A., Agarwala, V., Muddu, V., Ramaswamy, A., Chandrasekharan, A., Dhumal, S., Juvekar, S., Arya, A., Bhattacharjee, A., and Prabhash, K.
- Subjects
- *
PACLITAXEL , *CETUXIMAB , *CANCER chemotherapy , *CELECOXIB , *METHOTREXATE , *ANTINEOPLASTIC agents , *COMPARATIVE studies , *HEAD tumors , *RESEARCH methodology , *MEDICAL cooperation , *NECK tumors , *RESEARCH , *EVALUATION research - Abstract
Background: The present match pair analysis was planned to compare the efficacy of cetuximab-paclitaxel-based chemotherapy versus metronomic therapy.Materials and Methods: Sixty patients with metastatic/recurrent head and neck squamous cell cancer treated with weekly paclitaxel (80 mg/m2) and cetuximab were matched with sixty patients treated with oral metronomic chemotherapy consisting of methotrexate and celecoxib. The progression-free survival (PFS) and overall survival (OS) between the cohorts were compared using log-rank test. Cox proportional regression model was used to identify independent factors affecting PFS and OS.Results: The median OS was 191 days (95% confidence interval [CI]: 122.2-259.8 days) in metronomic cohort and 256 days (95% CI 177.0-334.9 days) in cetuximab cohort (hazard ratio: 0.58, 95% CI: 0.35-0.95, P = 0.031). On Cox proportional hazard model, Eastern Cooperative Oncology Group Performance Status (0-1 vs. 2) and therapy (cetuximab versus metronomic) had a statistically significant impact on OS.Conclusion: Cetuximab-based chemotherapy leads to a significant improvement in OS in the match pair analysis in comparison to metronomic chemotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients.
- Author
-
Zanwar, S., Noronha, V., Joshi, A., Patil, V. M., Chougule, A., Kumar, R., More, S., Goud, S., Janu, A., Mahajan, A., and Prabhash, K.
- Subjects
EPIDERMAL growth factor receptors ,NON-small-cell lung carcinoma ,PROTEIN-tyrosine kinases ,ASIANS ,BIOPSY ,DRUG resistance in cancer cells ,EPIDERMAL growth factor ,LUNG cancer ,GENETIC mutation ,PROTEIN kinase inhibitors - Abstract
Introduction: The feasibility and success rate of repeat biopsy for epidermal growth factor receptor (EGFR) mutation-positive lung cancers that have progressed on tyrosine kinase inhibitors (TKIs) are varied and merits further assessment.Materials and Methods: EGFR mutation-positive lung cancers were offered repeat biopsy upon progression on TKIs. Two groups of patients, first one on a clinical trial and second one from a database, were included for analysis. The feasibility to perform a repeat biopsy was analyzed in the first group. Success rate of biopsy and tissue adequacy for molecular testing was analyzed in both groups. Descriptive statistics were used for analyzing the demography, EGFR mutation type, tissue adequacy, and molecular profile at repeat biopsy. Kolmogorov-Smirnov test was used to assess normality of data. Two sample t-tests were used for comparison of proportions.Results: The feasibility of undergoing repeat biopsy was 77% (95% confidence interval [CI] of 69.4%-83.5%) in the first group (114/148 patients). Feasibility was not analyzed in the second group of patients. Out of 196 patients who underwent a repeat biopsy, 154 patients (78.6%; 95% CI: 72.2%-84.1%) had tumor tissue adequate for performing molecular testing. 27/196 (13.8%) patients did not have any evidence of malignancy on repeat biopsy whereas 15/196 (7.6%) patients had scanty tissue on repeat biopsy prohibiting molecular testing. Six patients (3.06%; 95% CI: 1.1%-6.5%) had small cell transformation. T790M mutation was detected in 12 out of the 42 patients (28.6%; 95% CI: 15.7-44.6) in whom EGFR testing was performed on repeat biopsy specimen.Conclusion: Repeat biopsy was able to provide adequate tissue acquisition in only two-thirds of the patients. Liquid biopsy represents an important tool to bridge this gap. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
18. Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3-4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors.
- Author
-
Joshi, A., Bhattacharjee, A., Noronha, V., Patil, V. M., Karpe, A., Kadam, N., Solanki, L., and Prabhash, K.
- Subjects
NON-small-cell lung carcinoma ,PROTEIN-tyrosine kinase inhibitors ,PLEURAL effusions ,ERLOTINIB ,GEFITINIB ,EPIDERMAL growth factor receptors ,PROTEIN kinase inhibitors ,LONGITUDINAL method ,LUNG cancer ,PROGNOSIS ,PROTEIN-tyrosine kinases ,TUMOR classification ,PREDICTIVE tests ,CHEMICAL inhibitors ,THERAPEUTICS - Abstract
Background: One of the ten advanced lung cancer patients presents with poor eastern cooperative oncology group performance status (ECOG PS). There are no clear guidelines about management of these patients. The benefit of tyrosine kinase inhibitors (TKI) in this patient population remains questionable. Hence, in this study, we attempted to develop and validate a predictive score which would predict benefit from oral TKI.Methods: This was a prospective observational study done at Tata Memorial Hospital, India. Patients with nonsmall cell lung cancer with ECOG PS 3-4 were included in this study. All these patients had received oral TKI on compassionate grounds and were followed up till death. The overall survival (OS) was calculated from date of start of TKI to date of death. R software was used for development and validation of the predictive model.Results: The median survival duration of the discovery cohort and validation cohort were 170.5 and 115 days, respectively. The model predicted OS accurately, within ±2 months in 72.1% and within ±3 months in 81.7% of patients.Conclusion: The current model can predict OS in poor PS patients treated with TKI within a satisfactory clinical range and can be used for decision-making of these patients. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
19. Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis.
- Author
-
Zanwar, S, Joshi, A, Noronha, V, Patil, V M, Sable, N, Popat, P, Menon, S, Kothari, R, Bhargava, P, Kapoor, A, and Prabhash, K
- Subjects
ANTINEOPLASTIC agents ,CANCER relapse ,DRUG therapy ,KIDNEY tumors ,PROGNOSIS ,RENAL cell carcinoma ,TREATMENT effectiveness ,ACQUISITION of data ,PROPORTIONAL hazards models ,KAPLAN-Meier estimator - Abstract
Aim: Patterns of care for metastatic renal cell carcinomas (mRCC) have seen tremendous reform in the last decade. Here, we present our pattern of care in second-line targeted therapy for mRCC.Methods: Patients with mRCC treated with second-line therapy were included from a prospective database. Demographics, risk stratification, and treatment details were noted. Event-free survival (EFS) and overall survival (OS) was calculated using Kaplan-Meier method. Log-rank test was used to identify factors affecting EFS and OS. Multivariate analysis was performed using cox regression.Results: Nearly 21.7% (46/212) of patients received second-line targeted treatment. Heng score for risk stratification showed 21.7% of patients in low risk, 36.9% in intermediate, and 34.8% in high risk group. Everolimus followed by pazopanib were the most common second-line therapies used in 65.2% and 13% of patients, respectively. The estimated median EFS was 3.5 months (95% confidence interval [CI] 2.7-4.26 months) and estimated median OS from the start of second-line therapy was 6.2 months (95% CI 3.4-9.0 months) with a median follow-up of 4.3 months. On univariate log-rank analysis, EFS of more than 6 months with first-line therapy was associated with improvement in EFS with second-line therapy (9.5 vs. 2.0 months; hazard ratio (HR) 0.364; P = 0.002). There was no factor independently associated with EFS or OS on multivariate analysis.Conclusion: Patterns of care for second line targeted therapy tend to vary with setting. A longer EFS with first-line therapy predicts improved outcomes with second-line treatment. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
20. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data.
- Author
-
A., Joshi, V., Agarwala, A., Ramaswamy, V., Noronha, V. M., Patil, S., Menon, P., Popat, N., Sable, K., Prabhash, Joshi, A, Agarwala, V, Ramaswamy, A, Noronha, V, Patil, V M, Menon, S, Popat, P, Sable, N, and Prabhash, K
- Subjects
RENAL cell carcinoma ,METASTASIS ,HYPERGLYCEMIA ,DYSLIPIDEMIA ,PROTEINURIA - Abstract
Introduction: Pazopanib is one of the recently introduced first-line therapeutic options in the treatment of metastatic renal cell carcinoma (mRCC). There is no published literature from India on the use of pazopanib in mRCC.Materials and Methods: We report the efficacy and toxicity analysis of first-line pazopanib therapy administered for patients with mRCC at our institute. It is a retrospective analysis of a prospectively maintained continuous data.Results: Between March 2013 and December 2015, 28 patients have been treated with pazopanib. The median age was 56.5 years with 23 males and five females. Sixty-eight percent patients had clear-cell histology. The most common site of metastasis was lung (75%), followed by bone (36%), liver (25%), and brain (14%) with 43% having more than one metastatic site. Partial response, stable disease, and progression were observed in 3 (11%), 10 (36%), and 4 (14%) cases, respectively, and the response was not evaluable in 11 patients. The median follow-up duration was 11.8 months, and progression-free survival was 5.9 months. Most of the toxicities were Grade I-II except in three patients who experienced Grade III hand-foot syndrome (HFS) and one patient who had Grade III anemia. Common side effects were hypertension, HFS, fatigue, transaminitis, hyperglycemia, dyslipidemia, and proteinuria which were quite manageable. No patient required treatment discontinuation due to toxicity.Conclusion: Based on this initial experience at our center, pazopanib seems a feasible first-line treatment for mRCC due to its well-tolerable toxicity profile. However, larger data are required to confirm its efficacy in Indian patients. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
21. A case series of salvage CCNU in high-grade glioma who have previously received temozolomide from a tertiary care institute in Mumbai.
- Author
-
V. M., Patil, R., Abhinav, R., Tonse, S., Epari, T., Gupta, R., Jalali, Patil, V M, Abhinav, R, Tonse, R, Epari, S, Gupta, T, and Jalali, R
- Subjects
GLIOMAS ,TEMOZOLOMIDE ,KAPLAN-Meier estimator ,BEVACIZUMAB ,MYELOSUPPRESSION - Abstract
Introduction: In our center, we routinely use CCNU (Lomustine) as salvage treatment in high-grade glioma patients who cannot afford bevacizumab. This exploratory analysis was done to report the efficacy and toxicity associated with this regimen.Methods: Patients who were treated with salvage CCNU (postexposure to temozolomide) between January 2015 and August 2016 were included for this retrospective analysis. SPSS version 16 was used for this analysis. Time-to-event analysis was performed using the Kaplan-Meier method. Progression-free survival (PFS) and overall survival (OS) were estimated. The maximum grade of toxicity during salvage CCNU was noted in accordance with CTCAE version 4.02.Results: In the stipulated period, 16 patients were selected for the analysis. The median age of patients was 43 years (range 15-63 years), and 12 (80.0%) patients were males. The Eastern Cooperative Oncology Group performance status was 0-1 in 11 patients (73.3%) and 2-4 in 4 patients (26.7%). The tumor histopathology at diagnosis was glioblastoma in ten patients (66.6%), anaplastic astrocytoma in four (26.7%) patients, and anaplastic oligodendroglioma in one patient (6.7%). Grade 3-4 myelosuppression was seen in five patients (33.3%). The median PFS and OS were 192 days (95% confidence interval [CI]: 156.0-227.5 days) and 282 days (95% CI: 190.9-373.1 days), respectively.Conclusion: CCNU is associated with modest treatment outcomes in recurrent/relapsed high-grade gliomas. The high rate of myelosuppression is a concern. Urgent efforts are required to improve upon these results. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
22. Pathomorphological changes of aceclofenac toxicity in layer chicks
- Author
-
Patel, N. J., primary, Joshi, B. P., additional, Prajapati, K. S., additional, and Patil, V. M., additional
- Published
- 2014
- Full Text
- View/download PDF
23. Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria.
- Author
-
A., Joshi, A., Ramaswamy, V., Noronha, V. M., Patil, A., Chandrasekharan, A., Goel, A., Sahu, N., Sable, A., Agrawal, S., Menon, K., Prabhash, Joshi, A, Ramaswamy, A, Noronha, V, Patil, V M, Chandrasekharan, A, Goel, A, Sahu, A, Sable, N, and Agrawal, A
- Subjects
SORAFENIB ,RENAL cell carcinoma ,METASTASIS ,MUCOSITIS ,DRUG dosage ,ANTINEOPLASTIC agents ,UREA ,CLINICAL trials ,COMPARATIVE studies ,KIDNEY tumors ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PROGNOSIS ,RESEARCH ,VITAMIN B complex ,EVALUATION research ,TREATMENT effectiveness ,VITAMIN therapy ,THERAPEUTICS - Abstract
Introduction: Sorafenib is an established upfront treatment option for metastatic RCC (mRCC). There is no published literature regarding its performance in Indian Patients. We present an analysis of Sorafenib use in our institute and attempt to validate the Heng criteria as a prognostic score in these patients.Materials and Methods: Patients who received Sorafenib as first line treatment for advanced RCC from June 2012 to December 2015 were prognosticated by Heng criteria and retrospectively analysed for baseline demographics, toxicity, response and outcomes.Results: 82 patients (65 males, 17 females) with a median age of 57 years were included for final analysis. Median ECOG PS was 1, 95.2 % of the patients had Stage IV disease and clear cell was the predominant histology (79.4%). 23.2%, 42.7% and 34.1% of patients were classified as low, intermediate and high risk by Heng's criteria, respectively. Dose reduction was required in 24.4% of patients, while 14.6% required permanent cessation of Sorafenib due to intolerable or recurrent side effects. Common adverse events included HFS (68.2%), mucositis (35.3%), fatigue (35.3%), rash (32.9%) and hypertension (25.6%). Response rate observed was 18.2%, while clinical benefit rate was 57.2% in the 57 patients where response was evaluable. Median progression free survival was 7.75 months (5.45-10.05) and median overall survival (OS) was 12.18 months (9.61 - 14.76). Median OS was 19.6, 16.1 and 10.3 months respectively for low, intermediate and high risk patients by Heng criteria and the criteria was statistically discriminatory for the 3 groups for OS (p=0.045, chi-square test).Conclusion: Sorafenib is a viable upfront treatment option for metastatic RCC in Indian patients with acceptable PFS, although a high incidence of HFS, mucositis and rash is observed. The Heng score has discriminatory value in mRCC with Sorafenib and can be considered for routine use in the clinic. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
24. Development and validation of a questionnaire to measure preferences and expectations of patients undergoing palliative chemotherapy: EXPECT questionnaire.
- Author
-
Patil, V. M., Chakraborty, S., Jithin, T. K., Dessai, S., Babu, T. P. Sajith, Raghavan, V., Geetha, M., Kumar, T. Shiva, Biji, M. S., Bhattacharjee, A., Nair, C., and Sajith Babu, T P
- Subjects
- *
PALLIATIVE treatment , *CANCER chemotherapy , *SELF-evaluation , *FEASIBILITY studies , *LONGITUDINAL method - Abstract
Objective: The objective was to design and validate the questionnaire for capturing palliative chemotherapy-related preferences and expectations.Design: Single arm, unicentric, prospective observational study.Methods: EXPECT questionnaire was designed to capture preferences and expectations of patients undergoing palliative chemotherapy. This questionnaire underwent a linguistic validation and then was tested in patients. Ten patients are undergoing chemotherapy for solid tumors who fulfilled the inclusion and exclusion criteria self-administered the EXPECT questionnaire in regional language. After filling this questionnaire, they self-administered quick questionnaire-10 (QQ-10). SPSS version 16 (IBM New York) was used for analysis. Completion rate of EXPECT questionnaire was calculated. The feasibility, face validity, utility and time taken for completion of EXPECT questionnaire was also assessed.Results: The completion rate of this questionnaire was 100%. All patients completed questionnaire within 5 min. The QQ-10 tool confirmed the feasibility, face validity and utility of the questionnaire.Conclusion: EXPECT questionnaire was validated in the regional language, and it's an effective tool for capturing patient's preferences and expectation from chemotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
25. An audit of cytoreductive surgeries in ovarian cancer from a rural based cancer center.
- Author
-
Dessai, S. B., Patil, V. M., Chakraborty, S., Babu, S., Bhattacharjee, A., Nayanar, S., Vikram, S., and Balasubramanian, S.
- Subjects
- *
OVARIAN cancer , *CYTOREDUCTIVE surgery , *DATA analysis , *BLOOD loss estimation , *DISEASE progression - Abstract
Background and Objective: Ovarian cancers are frequently seen at an advanced stage in our center. This audit was planned to see the morbidity and efficacy of different types of cytoreductive surgeries (radical vs. ultra-radical) done in such patients.Methods: This was a retrospective analysis of all ovarian cancer patients who underwent cytoreductive surgery at our center from January 2009 to August 2013. The case records of these patients were reviewed and the demographic, disease-related and treatment-related data were extracted.Results: Fifty-fivepatients were identified. Ten (18.2%) patients underwent primary cytoreduction while 45 patients had (81.8%) interval cytoreduction. The resections achieved were optimal in 50 patients (90.9%) and suboptimal in five patients (9.1%). The postoperative median blood loss was 400 (350-600) mL. The median time interval for surgery was 4.0 h (3-5 h). The type of resection achieved (optimal vs. suboptimal) was the only factor affecting the progression free survival (PFS) (Hazard ratio = 0.08 95% confidence interval 0.02-0.3). There was no significant difference in postoperative morbidity in patients undergoing the ultra-radical surgery as compared to those who underwent radical surgery.Conclusion: Optimal cytoreduction may improve PFS in advanced ovarian cancer patients and needs to be done even if it mandates an ultra-radical surgery. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
26. Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.
- Author
-
Dessai, S. B., Chakraborty, S., Babu, T. V. S., Nayanar, S., Bhattacharjee, A., Jones, J., Balasubramanian, S., Patil, V. M., and Babu, Tvs
- Subjects
PACLITAXEL ,CARBOPLATIN ,CANCER chemotherapy ,OVARIAN cancer patients ,DESCRIPTIVE statistics - Abstract
Objective: There are little data regarding safety and effectiveness of neoadjuvant chemotherapy (NACT) in patients who are considered unfit for receiving 3 weekly paclitaxel and carboplatin. The aim of this study was to study the toxicity and response rates of weekly paclitaxel and carboplatin as NACT in such cohort of patients.Methods: Study population included advanced ovarian cancer patients who were unlikely to tolerate 3 weekly paclitaxel and carboplatin and hence received weekly paclitaxel (80 mg/m2) and carboplatin AUC-2 as NACT. The data regarding the baseline characteristics, chemotherapy tolerance, completion rates, toxicity (CTCAE version 4.02), and radiological response rates are presented. SPSS version 16 was used for analysis. Descriptive statistics is presented.Result: Eleven patients received this schedule. Nine patients completed nine cycles of NACT. Except one, all patients completed NACT with an average relative dose intensity of >0.8. There was no chemotherapy-related mortality. Grade 3-4 life-threatening complications were seen in two patients. The post NACT response rate was 100%.Conclusion: Weekly paclitaxel and carboplatin chemotherapy is safe and efficacious in patients who are unsuitable for 3 weekly paclitaxel and carboplatin chemotherapy schedules. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
27. Does the use of induction chemotherapy in oral cavity cancer compromise subsequent loco-regional treatment delivery: Results from a matched pair analysis.
- Author
-
V. M., Patil, G., Muttath, S., Babu, S. T., Kumar, J., Jones, S., Sen, S., Chakraborty, Patil, V M, Muttath, G, Babu, S, Kumar, S T, Jones, J, Sen, S, and Chakraborty, S
- Subjects
CHEMOTHERAPY complications ,ADJUVANT treatment of cancer ,CANCER treatment ,CANCER complications ,CANCER patient care - Abstract
Background: Neoadjuvant chemotherapy is being increasingly used in patients with unresectable oral cavity cancers to make them resectable. However, its impact on locoregional treatment delivery in such setting remains poorly studied.Aims: To evaluate the impact of neoadjuvant chemotherapy on delivery of further locoregional treatment.Settings and Design: Mono institutional retrospective audit of patients with oral cavity squamous cell cancers treated with neoadjuvant triplet chemotherapy in India.Materials and Methods: Patients receiving neoadjuvant chemotherapy (n = 14) from May 2012 to April 2014 were matched 1:2 to patients undergoing upfront surgery (n = 28) based on age (>60 or 60 and less), gender (male or female) and subsite site (tongue and floor of mouth or buccoalveolar complex). Data regarding factors related to the delivery of locoregional treatment and toxicities were compiled.Statistical Analysis: Descriptive analysis in the form of median (range) for continuous variables and frequencies for categorical variables.Results: Patients undergoing neoadjuvant chemotherapy required more extensive resections and had greater operative time (460 vs. 415 min, P < 0.001). A greater incidence of locoregional wound complications was seen as a consequence (57.1% vs. 14.3%, P, 0.01). However, toxicities during radiotherapy were not substantially different between the two groups and compliance to radiation was also similar. Total package time of 100 days or less, was maintained in 90% of patients in both groups.Conclusions: Delivery of neoadjuvant chemotherapy does not impair the ability to deliver locoregional treatment. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
28. Retrospective audit of clinico-pathologic features and treatment outcomes in a cohort of elderly non-Hodgkin's lymphoma patients in a tertiary cancer center.
- Author
-
C. K., Nair, V. M., Patil, V., Raghavan, S., Babu, S., Nayanar, Nair, C K, Patil, V M, Raghavan, V, Babu, S, and Nayanar, S
- Subjects
LYMPHOMA diagnosis ,LYMPHOMA treatment ,LYMPHOMAS ,BREAST cancer diagnosis ,BREAST cancer treatment ,PATIENTS ,AUDITING ,LONGITUDINAL method ,PROGNOSIS ,SURVIVAL analysis (Biometry) ,TUMOR classification ,SPECIALTY hospitals ,TREATMENT effectiveness ,RETROSPECTIVE studies - Abstract
Introduction: There is limited data from India regarding elderly non-Hodgkin's lymphomas (NHL) patients. Hence, this audit was planned to study the clinic-pathological features and treatment outcomes in elderly NHL patients.Methods: Retrospective analysis of all NHL patients above age of 59 years treated at the author's institute, between December 2010 and December 2013 was done. Case records were reviewed for baseline details, staging details, prognostic factors, treatment delivered, response, toxicity and efficacy. SPSS version 16 (IBM, Newyork) was used for analysis. Descriptive statistics was performed. Kaplan-Meir survival analysis was done for estimation of progression-free survival (PFS) and overall survival (OS). Univariate analysis was done for identifying factors affecting PFS and OS.Results: Out of 141 NHL patients, 67 patients were identified subjected to the inclusion criteria. The median age was 68 years (60-92). Majority were B-cell NHL (86.6%). The commonest subtype in B-cell was diffuse large B-cell lymphoma (55.2%). Fifty-four patients took treatment. The treatment intent was curative in 41 patients (61.2%). Among the patients receiving curative treatment, 16 patients couldn't receive treatment in accordance with NCCN guidelines due to financial issues. Two years PFS was 55%. Two years PFS for B-cell NHL and T-cell NHL were 55% and 50% respectively (P = 0.982). Two years PFS for standard Rx and nonstandard Rx were 62% and 50% respectively, but it didn't reach statistical significance (P = 0.537). Two years OS for the entire cohort was 84%.Conclusion: Standard treatment in accordance with guidelines can be delivered in elderly patients irrespective of age. There is a need for creating financial assistance for patients, so that potentially curative treatments are not denied. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
29. ASSESSMENT OF GROUND WATER QUALITY STATUS USING NSFWQI METHOD IN SELECTED RURAL AREA OF KOPARGAON, AHMEDNAGAR, MAHARASHTRA
- Author
-
SASANE, V. V., primary and PATIL, V. M., additional
- Published
- 2012
- Full Text
- View/download PDF
30. Can point doses predict volumetric dose to rectum and bladder: a CT-based planning study in high dose rate intracavitary brachytherapy of cervical carcinoma?
- Author
-
Patil, V M, primary, Patel, F D, additional, Chakraborty, S, additional, Oinam, A S, additional, and Sharma, S C, additional
- Published
- 2011
- Full Text
- View/download PDF
31. Evaluating the potential of high micronaire cotton varieties for application in medical textiles: Using multiple linear regression models.
- Author
-
Gaikwad, S. G. and Patil, V. M.
- Abstract
Cotton breeder develops cotton varieties suitable for yarn production. Cotton buyers and spinners prefer to use micronaire range 3.5 to 4.9 and longer fiber length for the production of spun yarn. Buyers not purchasing high and low micronaire cotton because these fibers cause problems in yarn spinning. Therefore, in this project we selected cotton varieties inherendy have high micronaire. High volume instrument was used to determine the fiber properties and ten fiber properties were used to establish the relationship between the fiber properties and spinning consistency index, sinking time, water holding capacity of cotton varieties. This paper presents a regression equation of spinning consistency index, sinking time and water holding capacity of high micronaire cotton. The results shows that Elongation are statistically not significant variable in SCI,ST and WHC model. Developed Cotton varieties are superior in both the high micronaire value and short fiber length was identified. These coarse cotton varieties are best for the alternative application in medical textile. [ABSTRACT FROM AUTHOR]
- Published
- 2020
32. Head and neck cancer in geriatric patients: Analysis of the pattern of care given at a tertiary cancer care center.
- Author
-
Thiagarajan, S., Babu, T. P.S., Chakraborthy, S., Patil, V. M., Bhattacharjee, A., and Balasubramanian, S.
- Subjects
HEAD & neck cancer treatment ,HEALTH care industry ,DECISION making ,SQUAMOUS cell carcinoma ,PALLIATIVE treatment ,HEAD tumors ,NECK tumors ,SPECIALTY hospitals ,DIAGNOSIS ,TUMOR treatment - Abstract
Background and Aim: The percentage of elderly people with head and neck cancers (HNC) is on the rise. This makes HNC in this group of patients an important issue for healthcare providers. The present study was planned to analyze the patterns of care given to the geriatric patients and to identify the factors influencing the decision making process.Materials and Methods: Data of all the elderly patients (≥65 years) registered in the year 2012, with histologically proven HNC (all sites, stages, histopathological types, except lymphoma, sarcoma and cervical metastasis of unknown origin) receiving treatment (definitive/palliative) were collected.Results: A total of 270 patients were included in this study. The median age was 72 years (range: 65-101), with predominant male population (70%, n = 190). Oral cavity squamous cell carcinoma (SCC) was the most common cancer (57%, n = 154). Eastern Co-Operative Oncology Group performance status (PS) of 0-2 was seen in 91% of the patients. Co-morbidities were present in 139 (51.5%) patients. 50% (n = 134) of the patients received palliative intent treatment, 45% (n = 123) definitive treatment, whereas in 5% (n = 13) the intent was not mentioned. Age, a clinical stage and PS significantly influenced the decision making on the intent of treatment. 208 (77%) patients completed their treatment irrespective of the intent. Age was the only factor influencing treatment completion irrespective of the intent.Conclusion: Geriatric HNC patients frequently present with advanced disease, having multiple co-morbidities. Hence, a multidisciplinary team management of these patients is essential, also taking into account of the social and financial support available to these patients. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
33. Patterns of care in geriatric cancer patients - An audit from a rural based hospital cancer registry in Kerala.
- Author
-
Patil, V. M., Chakraborty, S., Dessai, S., Kumar, S. S., Ratheesan, K., Bindu, T., Geetha, M., Sujith, K., Babu, S., Raghavan, V., Nair, C. K., Syam, V., Surij, S., and Sathessan, B.
- Subjects
- *
OLDER patients , *CANCER treatment , *HEAD & neck cancer , *GASTROINTESTINAL cancer , *METASTASIS , *CANCER , *TUMOR classification , *GERIATRIC assessment , *TUMORS , *ACQUISITION of data - Abstract
Background: There is deficit of data from India on elderly patients with cancer. Comprehensive geriatric assessment may lead to a better decision making capacity in this population. However, routine implementation of such assessment is resource consuming.Aim: The aim of this study was to determine the patterns of care in elderly patients treated at a tertiary rural cancer center in India.Materials and Methods: All patients with age 70 or above with solid tumors without any definitive treatment prior to the registration at our center and registered between 01/01/2010 and 31/12/2011 were selected for this study. The baseline demographic pattern and the pattern of care of treatment were analyzed. SPSS version 16 (IBM Inc, Armonk, New York, U.S.) was used for analysis. Descriptive data are provided.Results: A total of 761 patients were evaluable subject to the aforementioned inclusion criteria. The median age of this cohort was 75 years (70-95 years). The most frequent primary sites of malignancies in 451 males were head neck (32.4%), lung (23.3%) and gastrointestinal (23.3%). In 310 females, the most common sites were head neck (31.6%), gynecological (18.4%) and gastrointestinal (24.5%). 228 (30%) of the patients had localized disease, 376 (49.4%) had loco-regionally advanced disease and 145 (19.1%) had distant metastases at presentation. 334 (46.32%) of patients were treated with curative intent. On logistic regression analysis the factors that predicted use of curative intent treatment were age <75 years, performance status 0-1, primary site and clinical extent of disease.Conclusion: Routine comprehensive geriatric assessment needs to be implemented in our setting as almost 50% of our geriatric patients undergo curative intent treatment. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
34. An audit of febrile neutropenia cases from a rural cancer center in India.
- Author
-
Patil, V. M., Chakarborty, S., Kumar, M. S., Geetha, M., Dev, S., Samuel, S., Ahmed, G., Nayanar, S. K., Vineetha, R., and Nair, C. K.
- Subjects
- *
FEBRILE neutropenia , *ANTIBIOTICS , *GRAM-negative bacteria , *CANCER chemotherapy - Abstract
Background: Data of febrile neutropenia (FN) from rural cancer centers is sparse. We did a audit of outcome of patients with FN in the period of March 2013-August 2013. The aim was to help us to develop rational antibiotic usage policies.Materials and Methods: Retrospective analysis of all consecutive patients presenting with FN. Data regarding demographic profile, tumor type, intent of treatment, chemotherapy regimen, blood culture susceptibility details, use of antibiotics, response to antibiotics and complications of FN were noted. SPSS (Statistical Product and Service Solutions) 16 was used for analysis.Results: 67 patients had FN and there were 91 episodes. The median day of presentation with FN after start of chemotherapy was 10 days. The nadir absolute neutrophil count was 161.5 and nadir platelet count 1,00,000. The median multinational association for supportive care in cancer (MASCC) Score was 24. In accordance with MASCC there were 27 high risk FN and 64 low risk FN episodes. On multivariate analysis using logistic regression MASCC score strata was the only significant variable that predicted failure to 1st line antibiotics (P = 0.03) and mortality (P = 0.01). Nine patients (9.9%) had positive isolates on blood cultures. The blood culture isolates were predominantly Gram negative (66.7%).Conclusion: The importance of developing local guidelines for rational antibiotic usage is highlighted. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
35. Pattern of infection, therapy, outcome and risk stratification of patients with febrile neutropenia in a tertiary care oncology hospital in India.
- Author
-
Noronha, V., Joshi, A., Patil, V. M., Bhosale, B., Muddu, V. K., Banavali, S., Kelkar, R., and Prabhash, K.
- Subjects
FEBRILE neutropenia ,NEUTROPENIA ,TERTIARY care ,CEPHALOSPORINS ,PATIENTS ,ANTIBIOTICS ,CANCER chemotherapy ,LEUKEMIA ,BACTERIAL diseases ,CANCER treatment ,DRUG resistance in microorganisms ,LYMPHOMAS ,RISK assessment ,TUMORS ,SPECIALTY hospitals ,RETROSPECTIVE studies - Abstract
Copyright of Indian Journal of Cancer is the property of Wolters Kluwer India Pvt Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2014
- Full Text
- View/download PDF
36. Referral pattern for neoadjuvant chemotherapy in the head and neck cancers in a tertiary care center.
- Author
-
Patil, V. M., Noronha, V., Joshi, A., Krishna, V. M., Dhumal, S., Chaudhary, V., Juvekar, S., Pai, P. S., Pankaj, C., Chaukar, D., Dcruz, A. K., and Prabhash, K.
- Subjects
- *
MEDICAL referrals , *HEAD & neck cancer treatment , *TERTIARY care , *TREATMENT effectiveness , *CANCER chemotherapy , *DISEASE prevalence - Abstract
BACKGROUND: Use of any treatment modality in cancer depends not only on the effectiveness of the modality, but also on other factors such as local expertise, tolerance of the modality, cost and prevalence of the disease. Oropharyngeal and laryngeal cancer are the major subsites in which majority of neoadjuvant chemotherapy (NACT) literature in the head and neck cancers is available. However, oral cancers form a major subsite in India. MATERIALS AND METHODS: This is an analysis of a prospectively maintained data on NACT in the head and neck cancers from 2008 to 2012. All these patients were referred for NACT for various indications from a multidisciplinary clinic. Descriptive analysis of indications for NACT in this data base is presented. RESULTS: A total of 862 patients received NACT within the stipulated time period. The sites where oral cavity 721 patients (83.6%), maxilla 41 patients (4.8%), larynx 33 patients (3.8%), laryngopharynx 8 patients (0.9%) and hypopharynx 59 patients (8.2%). Out of oral cancers, the major indication for NACT was to make the cancer resectable in all (100%) patients. The indication in carcinoma of maxilla was to make the disease resectable in 29 patients (70.7% of maxillary cancers) and in 12 patients (29.3% of maxillary cancers) it was given as an attempt to preserve the eyeball. The indication for NACT in laryngeal cancers was organ preservation in 14 patients (42.4% of larnyngeal cancer) and to achieve resectability in 19 patients (57.6% of larnyngeal cancer). The group with laryngopharynx is a cohort of eight patients in whom NACT was given to prevent tracheostomy, these patients had presented with early stridor (common terminology criteria for adverse events Version 4.02). The reason for NACT in hypopharyngeal cancers was for organ preservation in 24 patients (40.7% of hypopharyngeal cancer) and for achievement of resectability in 35 patients (59.3% of hypopharyngeal cancer). CONCLUSION: The major indication for NACT is to make disease resectable at our center while cases for organ preservation are few. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
37. Tolerance and toxicity of neoadjuvant docetaxel, cisplatin and 5 fluorouracil regimen in technically unresectable oral cancer in resource limited rural based tertiary cancer center.
- Author
-
Patil, V. M., Chakraborty, S., Shenoy, P. K., Manuprasad, A., Sajith Babu, T. P., Shivkumar, T., Babu, S., Bhatterjee, A., and Balasubramanian, S.
- Subjects
- *
DOCETAXEL , *CISPLATIN , *ORAL cancer , *SURGICAL excision , *DRUG administration , *BIOPSY - Abstract
BACKGROUND: Recent studies indicate neoadjuvant chemotherapy (NACT) can result in R0 resection in a substantial proportion of patients with technically unresectable oral cavity cancers. However, data regarding the efficacy and safety of docetaxel, cisplatin and 5 fluorouracil (TPF) NACT in our setting is lacking. The present audit was proposed to evaluate the toxicities encountered during administration of this regimen. It was hypothesized that TPF NACT would be considered feasible for routine administration if an average relative dose intensity (ARDI) of ⩾0.90 or more in at least 70% of the patients. MATERIALS AND METHODS: Technically unresectable oral cancers with Eastern Cooperative Oncology Group PS 0-2, with biopsy proven squamous cell carcinoma underwent two cycles of NACT with TPF regimen. Toxicity and response rates were noted following the CTCAE 4.03 and RECIST criteria. Descriptive analysis of completion rates (completing 2 cycles of planned chemotherapy with ARDI of 0.85 or more), reason for delay, toxicity, and response are presented. RESULTS: The NACT was completed by all patients. The number of subjects who completed all planned cycles of chemotherapy are with the ARDI of the delivered chemotherapy been equal to or >0.85 was 11 (91.67%). All toxicity inclusive Grade 3-5 toxicity was seen in 11 patients (91.67%). The response rate of chemotherapy was 83.33%. There were three complete response, seven partial response, and two stable disease seen post NACT in this study. CONCLUSION: Docetaxel, cisplatin and 5 fluorouracil regimen can be routinely administered at our center with the supportive care methods and precautionary methods used in our study. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
38. Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers?
- Author
-
Joshi, A., Patil, V. M., Noronha, V., Juvekar, S., Deshmukh, A., Chatturvedi, P., Chaukar, D. A., Agarwal, J. P., Ghosh, S., Murthy, V., D'cruz, A., and Prabhash, K.
- Subjects
- *
CANCER patients , *ORAL cancer , *THERAPEUTICS , *DRUG therapy , *SURGICAL excision - Abstract
OBJECTIVE: The objective of the following study is to investigate the efficacy and impact of induction chemotherapy in T4b oral cavity cancers. MATERIALS AND METHODS: It's a retrospective analysis of prospectively collected data of T4b oral cavity cancer patients who were offered induction chemotherapy and then assessed for resectability at the end of 2 cycles of chemotherapy. Post-induction these patients either underwent surgical or non-surgical local intervention depending upon their response. These patients were then followed-up until either recurrence progression or death whichever was later. Statistical analysis was performed by SPSS version 16. Descriptive analysis was performed. Factors affecting achievement of resectability were sought by univariate and multivariate analysis. The impact of surgery on overall survival (OS) was studied using Kaplan Meier survival analysis with the use of log rank test. RESULTS: A total of 110 patients received chemotherapy. Median age been 41.5 years (range 25-66 years). 21 (20%) of our patient received 3 drug regimen while the rest of our patients received 2 drug regimen. Partial response was achieved in 28 patients, stable disease in 49 patients and progression was noted in 23 patients. Resectability was achieved in 34 (30.9%) of 110 patients. The estimated median OS in patients who underwent surgery was 18.0 months (95% confidence interval [CI]: 13.6-22.46 months) and for those treated with non-surgical treatment was 6.5 months (95% CI: 5.6-7.4 months) (P = 0.0001). CONCLUSION: Use of induction chemotherapy is safe and can achieve resectability in 30.9% of our T4b patients. In those patients undergoing resection have much better OS then those who underwent non-surgical local treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
39. Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer.
- Author
-
Noronha, V., Patil, V. M., Joshi, A., and Prabhash, K.
- Subjects
- *
LUNG cancer , *SMALL cell carcinoma , *APLASTIC anemia , *REFRACTORY materials , *CANCER treatment , *ANTINEOPLASTIC agents , *CANCER patients - Abstract
CONTEXT: There are limited effective therapeutic options in the relapsed setting for non-small cell lung cancer (NSCLC) or in the first line for platinum-ineligible patients. AIM: To evaluate the safety and efficacy of a metronomic schedule of paclitaxel administered weekly in relapsed refractory NSCLC or upfront in patients not eligible for platinum-based chemotherapy. SETTINGS AND DESIGN: Retrospective analysis of a prospectively collected database from the medical oncology department at Tata Memorial Hospital in Mumbai, India. MATERIALS AND METHODS: Patients with recurrent and treatment-naïve platinum-ineligible advanced NSCLC were treated with weekly paclitaxel at 80 mg/m2 with palliative intent. Restaging scans were obtained every two months. Chemotherapy was continued until progressive disease, intolerable side effects, or decision of the patient. STATISTICAL ANALYSIS USED: SPSS version 16 was used for analysis. Simple percentages were used for descriptive statistics. Progression-free survival (PFS) was calculated from date of start of paclitaxel till the date of progression, change of therapy due to any reason, or death due to any cause. Overall survival (OS) was calculated from date of start of paclitaxel to death. The Kaplan Meier method was used for estimation of survival. RESULTS: There were 37 patients over eight months. The median age was 59 years, with a male-to-female ratio of 5:1. Two patients received paclitaxel in the first line, 18 patients in second line, nine in third line, five in fourth line, and three were in fifth line. 73% patients had received prior platinum and 48.6% patients had Eastern Cooperative Oncology Group performance status (ECOG PS) >2. The median number of weekly cycles delivered was 14. The response rate was 35% [complete remission (CR): 2.7%, partial remission (PR): 32.4%, stable disease (SD): 32.4%, progressive disease (PD): 27%], the median PFS was four months, and the estimated median OS was seven months. Chemotherapy was well tolerated. The most frequent grade 3 toxicities included anemia: 8%, neutropenia: 5.4%, and sensory neuropathy: 8%. There were no grade 4 toxicities and no episodes of febrile neutropenia. CONCLUSIONS: Weekly low-dose continuous metronomic-type scheduling of paclitaxel is safe and effective for relapsed refractory NSCLC and in the first line in platinum-ineligible patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
40. Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference?
- Author
-
Patil, V. M., Noronha, V., Muddu, V. K., Gulia, S., Bhosale, B., Arya, S., Juvekar, S., Chatturvedi, P., Chaukar, D. A., Pai, P., D'cruz, A., and Prabhash, K.
- Subjects
- *
TREATMENT of oral cancer , *CANCER chemotherapy , *CANCER prognosis , *DISEASE complications , *FEBRILE neutropenia - Abstract
BACKGROUND: Locally advanced and unresectable oral cavity cancers have a poor prognosis. Induction might be beneficial in this setting by reducing tumor bulk and allowing definitive surgery. AIM: To analyze the impact of induction chemotherapy on locally advanced, technically unresectable oral cavity cancers. MATERIALS AND METHODS: Retrospective analysis of patients with locally advanced oral cavity cancers, who were treated with neoadjuvant chemotherapy (NACT) during the period between June 2009 and December 2010. Data from a prospectively filled database were analyzed for information on patient characteristics, chemotherapy received, toxicity, response rates, local treatment offered, patterns of failure, and overall survival. The statistical analysis was performed with SPSS version 16. RESULTS: 123 patients, with a median age of 42 years were analyzed. Buccal mucosa was the most common subsite (68.30%). Three drug regimen was utilized in 26 patients (21.10%) and the rest received two drug regimen. Resectability was achieved in 17 patients treated with 3 drug regimen (68.00%) and 36 patients receiving 2 drug regimen. Febrile neutropenia was seen in 3 patients (3.09%) receiving 2 drug regimen and in 9 patients (34.62%) receiving 3 drug regimen. The estimated median OS was not reached in patients who had clinical response and underwent surgery as opposed to 8 months in patients treated with non-surgical modality post NACT (P = 0.0001). CONCLUSION: Induction chemotherapy was effective in converting technically unresectable oral cavity cancers to operable disease in approximately 40% of patients and was associated with significantly improved overall survival in comparison to nonsurgical treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
41. Weekly cisplatin (30-40 mg/m2) as radiosensitizer: Is it high or moderate emetic agent?
- Author
-
A., Karpe, V. M., Patil, A., Joshi, V., Noronha, S., Gupta, A., Ramaswamy, A., Sahu, V., Doshi, T., Gupta, S., Rath, S., Banavali, K., Prabhash, Karpe, A, Patil, V M, Joshi, A, Noronha, V, Gupta, S, Ramaswamy, A, Sahu, A, and Doshi, V
- Subjects
ANTIEMETICS ,PREVENTIVE medicine ,CISPLATIN ,RADIATION-sensitizing agents ,CANCER chemotherapy - Abstract
Purpose: The American Society of Clinical Oncology (ASCO) guideline recommends a high antiemetic prophylaxis for any dose of cisplatin. This hypothesis was tested by us in this analysis of solid tumor patients who received weekly cisplatin as a radiosensitizer in a dose range of 30-40 mg/m2.Methods: This was a retrospective analysis of 181 solid tumor patients who received weekly cisplatin (in the dose range of 30-40 mg/m2) as a radiosensitizer between July 2015 and August 2015. The antiemetic prophylaxis schedule provided was classified as optimal (if a high antiemetic prophylaxis was provided) or suboptimal (if a nonhigh antiemetic prophylaxis was provided). The incidence of acute, delayed and breakthrough vomiting after chemotherapy was noted. SPSS version 20 was used for analysis. Fisher's exact test was used to determine the association between antiemetic schedule (suboptimal vs. optimal) and postchemotherapy emesis.Results: In the present study, of 181 patients, only 25 patients (13.8%) received optimal antiemetic prophylaxis while the remaining 156 (86.2%) received suboptimal prophylaxis. In the cohort of patients with suboptimal prophylaxis, dexamethasone was omitted in all patients (100%) while NK receptor antagonist was omitted in 76 patients (48.7%). The rate of vomiting was lower in patients receiving optimal prophylaxis as compared to that in patients receiving suboptimal prophylaxis (12% vs. 39.75%; P - 0.005).Conclusion: Omission of dexamethasone followed by aprepitant was the main reason for suboptimal prophylaxis. High antiemetic prophylaxis in accordance with ASCO guidelines overall decreased the risk of emesis in patients receiving CTRT with weekly cisplatin in the dose range of 30-40 mg/m2. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
42. Predictivity of human papillomavirus positivity in advanced oral cancer.
- Author
-
Kane, S., Patil, V. M., Noronha, V., Joshi, A., Dhumal, S., D'Cruz, A., Bhattacharjee, A., and Prabhash, K.
- Subjects
- *
PAPILLOMAVIRUSES , *ORAL cancer , *HEALTH , *SMOKING , *SMOKELESS tobacco , *LOGICAL prediction , *LONGITUDINAL method , *MOUTH tumors , *PAPILLOMAVIRUS diseases - Abstract
Background and Objective: Human papillomavirus (HPV) is a known prognostic factor world over in patients of carcinoma oropharynx. The role of HPV in oral cancers has not been investigated adequately. We tried to identify standard clinicopathological features in oral cancer, which would predict HPV-positivity.Methods: This was a retrospective analysis of 124 cases of T4 oral cancer patients at our center. HPV-positive was defined in accordance with positive p16 immunohistochemistry done on pretreatment local tumor site biopsy. Age, sex, habits (smoking history and oral tobacco), Eastern Cooperative Oncology Group performance status (ECOG PS), T stage, N stage, grade, and site were selected, for testing of prediction for HPV-positivity. The analysis was performed by R studio version 3.1.1. Two-sample test for equality of proportions with continuity correction was used to identify factors predicting for HPV-positivity. P = 0.05 was considered as significant.Results: Of 124 patients, 16 patients (12.9%) were HPV-positive. The median age of the whole cohort was 43 years (interquartile range 37-52 years) with 15 females (12.1%). All had squamous cell carcinoma (100%). The grade of the tumor was well differentiated in 9 patients (7.2%), moderately differentiated in 98 patients (79.1%), and poorly differentiated in 17 patients (13.7%). The ECOG PS 0 in 19 patients (15.3%), 1 in 104 patients (83.9%), and 2 in 1 patient (0.8%). The subsite of the tumor was buccal mucosa in 74 patients (59.7%), anterior two-third of tongue in 33 patients (26.6%), and others in 17 patients (13.7%). None of the tested factors except the use of oral tobacco were statistically significantly associated with HPV-positivity. History of tobacco usage had a statistical trend toward ability to predict HPV-positivity. The proportion of patients with HPV-positive oral cancer in patients without history usage of oral tobacco was 31.3% while it was 10.2% in patients with previous history of tobacco use (P = 0.03).Conclusion: Standard clinicopathological variables could not predict for HPV-positivity. Negative history of tobacco (smokeless) usage showed statistical trends toward ability to predict HPV-positivity in oral cancer patients. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
43. Recurrent sinonasal teratocarcinosarcoma with intracranial extension: Case report.
- Author
-
Joshi, A., Dhumal, S. B., Manickam, D. R., Noronha, V., Bal, M., Patil, V. M., and Prabhash, K.
- Subjects
SARCOMA ,CANCER ,TUMORS - Abstract
A letter to the editor is presented commenting on the case history of a patient with recurrent sinonasal teratocarcinosarcoma with intracranial extension.
- Published
- 2014
- Full Text
- View/download PDF
44. Composites based on eri-silk with unsaturated polyester resin.
- Author
-
Agrawal, S. K., Patil, V. M., and Tayde, S. S.
- Published
- 2016
45. 57PMultidisciplinary brain metastasis clinic: Is it effective and worthwhile?
- Author
-
Rajpurohit, A, Patil, V M, Noronha, V, Joshi, A, Menon, N, Puranik, A, Purandare, N, Mahajan, A, Mummudi, N, Krishnatry, R, Kumar, R, Yadav, S, and Prabhash, K
- Subjects
- *
BRAIN metastasis , *EPIDERMAL growth factor receptors - Abstract
Background Management of brain metastasis is a complex multidisciplinary venture. Hence, we started a multidisciplinary brain metastasis clinic for opinion on difficult brain metastasis cases. This is the review of the impact of this clinic on the treatment decisions. Methods Brain metastasis clinic (BMC) was started in the month of April 2018 and meets once a week. Data of patients discussed between 27th April 2018 to 28th June 2019 were included for thisanalysis. Treatment decision made by clinicians (before sending the patient to the BMC were compared with the decisions made in BMC. The decisions were broken on a predefined proforma as intent of treatment (curative or palliative), modalities planned (surgery, radiation, chemotherapy), type of therapy planned (details of each therapy) in each modality were collected both pre and post BMC. In addition, compliance of the respective physicians to BMC decision was also calculated. SPSS version 20 was used for analysis. Descriptive statistics was performed. Results Ninety-nine patients were discussed in this time period. The median age was 51 (range 17-68) years. The gender distribution was 70 males (70.7%) and 29 females (29.3%). Lung was thepredominant site of malignancy (79, 79.8%). Thirty-one patients (31.3%) had EGFR TKI domain activating mutation while 17 (17.2%) had ALK rearrangement. The treatment plan was changed in 46 patients (46.5%). The intent of treatment was changed in 5 patients (5.3%). Change in treatment plan with respect to surgery in 9 patients (9.1%), radiation in 37 patients (37.4%), chemotherapy in 15 patients (15.2%), targeted therapy in 11 patients (22.9%) and intrathecal in 6 patients (6.1%) respectively. The compliance to the BMC decision in patients in whom it was changed was 84.8% (39, n = 46). Conclusions Multidisciplinary management of difficult brain metastasis cases in specialized clinics has significant impact on treatment decisions. Legal entity responsible for the study Tata Memorial Hospital, Mumbai. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
46. Expanded panel test detecting mesenchymal-epithelial transition amplification leading to effective treatment in adenocarcinoma lung.
- Author
-
Noronha, V. M., Jandyal, S., Joshi, A., Patil, V. M., Mahajan, A., and Prabhash, K.
- Subjects
ADENOCARCINOMA ,EPIDERMAL growth factor receptors ,CANCER chemotherapy - Published
- 2017
- Full Text
- View/download PDF
47. Study of incidence, innervation and clinical importance of axillary arch of langer
- Author
-
MALLIKARJUN ADIBATTI, Ramesh, C. M., Patil, V. M., and Vijayanath, V.
48. NEEDLE PUNCHING PROCESS--A REVIEW.
- Author
-
Patil, B. M., Patil, V. M., and Goud, V. A.
- Abstract
The nonwoven manufacturing method basically consists of web laying and web bonding. Among the web bonding methods needle punching is a very exciting and diverse trade involving technology for natural, synthetic fibres and their blends. Needle punching technique has been used in industry since 1870s. The needle-punching process is very commonly used to manufacture medium to heavy weight nonwoven fabrics. The bonding of webs by using needle punching technique is now a day's extensively utilized for the production of numerous products which not only competes with the conventionally used textiles, but exhibit properties hitherto unknown and not attainable by any other method. This paper cover a few area regarding type of bonding, needle punching process, needle structures, different types of needle loom parameters influencing the process and application of product in various field. [ABSTRACT FROM AUTHOR]
- Published
- 2014
49. ChemInform Abstract: STUDIES IN BENZOFURANS: PART XV - CURTIUS REARRANGEMENT AND OTHER REACTIONS OF ETHYL 3-CARBETHOXYAMINO-2-BENZOFURANCARBOXYLATE
- Author
-
PATIL, V. M., primary, SANGAPURE, S. S., additional, and AGASIMUNDIN, Y. S., additional
- Published
- 1984
- Full Text
- View/download PDF
50. ChemInform Abstract: SYNTHESIS OF NEW HETEROCYCLES- PART XVIII. SYNTHESIS OF SPIROCYCLIC OXAZOLO(3,4-A)PYRIDINES AND PYRIDO(1,2-C)(1,3)OXAZINES
- Author
-
ARYA, V. P., primary, SHENOY, S. J., additional, and PATIL, V. M., additional
- Published
- 1977
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.